|
|
Volumn 203, Issue 1, 2001, Pages 38-44
|
|
Acne resolution rates: Results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara®) and EE/LNG (Microgynon®)
a
|
|
Author keywords
Acne; Androgenization; Chlormadinone acetate; Ethinylestradiol; Levonorgestrel; Oral contraceptive
|
|
Indexed keywords
ANTIANDROGEN;
CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL;
ETHINYLESTRADIOL PLUS LEVONORGESTREL;
ORAL CONTRACEPTIVE AGENT;
PROGESTERONE;
UNCLASSIFIED DRUG;
ACNE;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DRUG EFFICACY;
DYSMENORRHEA;
HEADACHE;
HIRSUTISM;
HUMAN;
MULTICENTER STUDY;
NAUSEA;
PAPULE;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PUSTULE;
RANDOMIZED CONTROLLED TRIAL;
SINGLE BLIND PROCEDURE;
TREATMENT OUTCOME;
ACNE VULGARIS;
ADOLESCENT;
ADULT;
ALOPECIA;
ANDROGEN ANTAGONISTS;
CHLORMADINONE ACETATE;
CONTRACEPTIVES, ORAL, SYNTHETIC;
DERMATITIS, SEBORRHEIC;
ETHINYL ESTRADIOL;
ETHINYL ESTRADIOL-NORGESTREL COMBINATION;
FEMALE;
HIRSUTISM;
HUMANS;
SINGLE-BLIND METHOD;
TREATMENT OUTCOME;
|
|
EID: 0034838348
PISSN: 10188665
EISSN: None
Source Type: Journal
DOI: 10.1159/000051701 Document Type: Article |
|
Times cited : (89)
|
|
References (16)
|
